You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmineptine
Accession NumberDB04836
TypeSmall Molecule
GroupsIllicit, Withdrawn
DescriptionThe Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until 2005.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DirectimNot Available
ManeonNot Available
NeoliorNot Available
ProvectorNot Available
SurvectorServier
ViasperaNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Amineptine hydrochloride
Thumb
  • InChI Key: VDPUXONTAVMIKZ-UHFFFAOYSA-N
  • Monoisotopic Mass: 373.180856852
  • Average Mass: 373.916
DBSALT000803
Categories
UNII27T1I13L6G
CAS number57574-09-1
WeightAverage: 373.916
Monoisotopic: 373.180856852
Chemical FormulaC22H28ClNO2
InChI KeyInChIKey=VDPUXONTAVMIKZ-UHFFFAOYSA-N
InChI
InChI=1S/C22H27NO2.ClH/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22;/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25);1H
IUPAC Name
N-(6-carboxyhexyl)tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-aminium chloride
SMILES
[Cl-].OC(=O)CCCCCC[NH2+]C1C2=CC=CC=C2CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Carbocyclic fatty acid
  • Medium-chain fatty acid
  • Aralkylamine
  • Fatty acyl
  • Fatty acid
  • Quaternary ammonium salt
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic chloride salt
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression.
PharmacodynamicsAmineptine is an atypical tricyclic antidepressant.
Mechanism of actionAmineptine selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life48 minutes for the parent drug and 2.5 hours for the metabolites.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.927
Blood Brain Barrier+0.9384
Caco-2 permeable-0.5548
P-glycoprotein substrateNon-substrate0.5457
P-glycoprotein inhibitor INon-inhibitor0.9324
P-glycoprotein inhibitor IINon-inhibitor0.8538
Renal organic cation transporterNon-inhibitor0.6998
CYP450 2C9 substrateNon-substrate0.7559
CYP450 2D6 substrateNon-substrate0.7653
CYP450 3A4 substrateNon-substrate0.5897
CYP450 1A2 substrateNon-inhibitor0.5434
CYP450 2C9 inhibitorNon-inhibitor0.8792
CYP450 2D6 inhibitorNon-inhibitor0.7593
CYP450 2C19 inhibitorNon-inhibitor0.8446
CYP450 3A4 inhibitorNon-inhibitor0.7073
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9165
Ames testAMES toxic0.6805
CarcinogenicityNon-carcinogens0.8651
BiodegradationNot ready biodegradable0.7096
Rat acute toxicity2.9526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9341
hERG inhibition (predictor II)Inhibitor0.6018
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226-230Melen,C., Danree, B.and Poignant, J.C.; US.Patent 3,758,528; September 11,1973; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale Melen, C., Danree, B. and Poignant, J.C.; U.S. Patent 3,821,249; June 28, 1974; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale
Predicted Properties
PropertyValueSource
Water Solubility1.84e-05 mg/mLALOGPS
logP0.99ALOGPS
logP2.74ChemAxon
logS-7.3ALOGPS
pKa (Strongest Acidic)4.41ChemAxon
pKa (Strongest Basic)9.46ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area53.91 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity112.63 m3·mol-1ChemAxon
Polarizability39.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Melen,C., Danree, B.and Poignant, J.C.; US.Patent 3,758,528; September 11,1973; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale.
Melen, C., Danree, B. and Poignant, J.C.; U.S. Patent 3,821,249; June 28, 1974; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale.

US3758528
General References
  1. Vaugeois JM, Corera AT, Deslandes A, Costentin J: Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor. Pharmacol Biochem Behav. 1999 Jun;63(2):285-90. [PubMed:10371658 ]
  2. Grupper C: [New iatrogenic acne: acne caused by amineptin (Survector)]. Ann Dermatol Venereol. 1988;115(11):1174-6. [PubMed:2977079 ]
  3. Thioly-Bensoussan D, Charpentier A, Triller R, Thioly F, Blanchet P, Tricoire N, Noury JY, Grupper C: [Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases]. Ann Dermatol Venereol. 1988;115(11):1177-80. [PubMed:2977080 ]
  4. Vexiau P, Gourmel B, Husson C, Castot A, Rybojad M, Julien R, Fiet J, Puissant A, Cathelineau G: [Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases]. Ann Dermatol Venereol. 1988;115(11):1180-2. [PubMed:2977081 ]
  5. Teillac D, Weber MJ, Lowenstein W, de Prost Y: [Acne caused by Survector]. Ann Dermatol Venereol. 1988;115(11):1183-4. [PubMed:2977082 ]
External Links
ATC CodesN06AA19
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Amineptine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Amineptine can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetamineAmineptine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineAmineptine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Amineptine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Amineptine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Amineptine.
AcenocoumarolAmineptine may increase the anticoagulant activities of Acenocoumarol.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Amineptine.
AlogliptinThe serum concentration of Amineptine can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Amineptine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Amineptine.
AmobarbitalThe metabolism of Amineptine can be increased when combined with Amobarbital.
AmphetamineAmineptine may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Amineptine can be increased when it is combined with Amprenavir.
Antithrombin III humanThe serum concentration of Amineptine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Amineptine can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Amineptine.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Amineptine.
AprotininThe serum concentration of Amineptine can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Amineptine is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Arformoterol.
ArgatrobanThe serum concentration of Amineptine can be increased when it is combined with Argatroban.
AsunaprevirThe serum concentration of Amineptine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Amineptine can be increased when it is combined with Atazanavir.
BambuterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Bambuterol.
BarbitalThe metabolism of Amineptine can be increased when combined with Barbital.
BatimastatThe serum concentration of Amineptine can be increased when it is combined with Batimastat.
BenazeprilThe serum concentration of Amineptine can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the serotonergic activities of Amineptine.
BenzamidineThe serum concentration of Amineptine can be increased when it is combined with Benzamidine.
BenzphetamineAmineptine may increase the stimulatory activities of Benzphetamine.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Amineptine.
BivalirudinThe serum concentration of Amineptine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Amineptine can be increased when it is combined with Boceprevir.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Amineptine.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amineptine.
BupropionThe metabolism of Amineptine can be decreased when combined with Bupropion.
CandoxatrilThe serum concentration of Amineptine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Amineptine can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Amineptine can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the serotonergic activities of Amineptine.
CeliprololThe risk or severity of adverse effects can be increased when Amineptine is combined with Celiprolol.
ChlorphentermineAmineptine may increase the stimulatory activities of Chlorphentermine.
ChymostatinThe serum concentration of Amineptine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Amineptine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Amineptine can be increased when it is combined with Cilazapril.
CimetidineThe metabolism of Amineptine can be decreased when combined with Cimetidine.
CinacalcetThe serum concentration of Amineptine can be increased when it is combined with Cinacalcet.
CirazolineAmineptine may increase the vasopressor activities of Cirazoline.
CitalopramThe risk or severity of adverse effects can be increased when Amineptine is combined with Citalopram.
ClenbuterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Clenbuterol.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Amineptine.
Dabigatran etexilateThe serum concentration of Amineptine can be increased when it is combined with Dabigatran etexilate.
DarunavirThe serum concentration of Amineptine can be increased when it is combined with Darunavir.
DesmopressinThe risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Amineptine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Amineptine.
DextroamphetamineAmineptine may increase the stimulatory activities of Dextroamphetamine.
DicoumarolAmineptine may increase the anticoagulant activities of Dicoumarol.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Amineptine.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Amineptine.
DobutamineThe risk or severity of adverse effects can be increased when Amineptine is combined with Dobutamine.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Amineptine.
DuloxetineDuloxetine may increase the serotonergic activities of Amineptine.
EcabetThe serum concentration of Amineptine can be increased when it is combined with Ecabet.
EdoxabanThe serum concentration of Amineptine can be increased when it is combined with Edoxaban.
ElafinThe serum concentration of Amineptine can be increased when it is combined with Elafin.
EnalaprilThe serum concentration of Amineptine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Amineptine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Amineptine can be increased when it is combined with Enalkiren.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Amineptine.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Amineptine.
ErgotamineAmineptine may increase the vasopressor activities of Ergotamine.
EscitalopramThe risk or severity of adverse effects can be increased when Amineptine is combined with Escitalopram.
Ethyl biscoumacetateAmineptine may increase the anticoagulant activities of Ethyl biscoumacetate.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Amineptine.
FenoterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Fenoterol.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amineptine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amineptine.
FormoterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Formoterol.
FosamprenavirThe serum concentration of Amineptine can be increased when it is combined with Fosamprenavir.
FosinoprilThe serum concentration of Amineptine can be increased when it is combined with Fosinopril.
FurazolidoneFurazolidone may increase the serotonergic activities of Amineptine.
GeldanamycinThe serum concentration of Amineptine can be increased when it is combined with Geldanamycin.
GM6001The serum concentration of Amineptine can be increased when it is combined with GM6001.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Amineptine.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Amineptine.
HexobarbitalThe metabolism of Amineptine can be increased when combined with Hexobarbital.
HirulogThe serum concentration of Amineptine can be increased when it is combined with Hirulog.
HydracarbazineHydracarbazine may increase the serotonergic activities of Amineptine.
Hydroxyamphetamine hydrobromideAmineptine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
IndacaterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Indacaterol.
IndinavirThe serum concentration of Amineptine can be increased when it is combined with Indinavir.
IproclozideIproclozide may increase the serotonergic activities of Amineptine.
IproniazidIproniazid may increase the serotonergic activities of Amineptine.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Amineptine.
IsoetarineThe risk or severity of adverse effects can be increased when Amineptine is combined with Isoetarine.
IsoflurophateThe serum concentration of Amineptine can be increased when it is combined with Isoflurophate.
IsoprenalineThe risk or severity of adverse effects can be increased when Amineptine is combined with Isoprenaline.
IxazomibThe serum concentration of Amineptine can be increased when it is combined with Ixazomib.
LepirudinThe serum concentration of Amineptine can be increased when it is combined with Lepirudin.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Amineptine.
LinagliptinThe serum concentration of Amineptine can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Amineptine.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Amineptine.
LiotrixLiotrix may increase the arrhythmogenic activities of Amineptine.
LisdexamfetamineAmineptine may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Amineptine can be increased when it is combined with Lisinopril.
LithiumLithium may increase the neurotoxic activities of Amineptine.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Amineptine.
LopinavirThe serum concentration of Amineptine can be increased when it is combined with Lopinavir.
MebanazineMebanazine may increase the serotonergic activities of Amineptine.
MephentermineAmineptine may increase the stimulatory activities of Mephentermine.
MetaraminolAmineptine may increase the vasopressor activities of Metaraminol.
MethamphetamineAmineptine may increase the stimulatory activities of Methamphetamine.
MethohexitalThe metabolism of Amineptine can be increased when combined with Methohexital.
MethoxamineAmineptine may increase the vasopressor activities of Methoxamine.
Methylene blueAmineptine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amineptine.
MethylphenobarbitalThe metabolism of Amineptine can be increased when combined with Methylphenobarbital.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amineptine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Amineptine.
MidodrineAmineptine may increase the vasopressor activities of Midodrine.
MinaprineMinaprine may increase the serotonergic activities of Amineptine.
MoclobemideMoclobemide may increase the serotonergic activities of Amineptine.
MoexiprilThe serum concentration of Amineptine can be increased when it is combined with Moexipril.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Amineptine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Amineptine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Amineptine.
NCX 4016The serum concentration of Amineptine can be increased when it is combined with NCX 4016.
NelfinavirThe serum concentration of Amineptine can be increased when it is combined with Nelfinavir.
NialamideNialamide may increase the serotonergic activities of Amineptine.
NicorandilAmineptine may increase the hypotensive activities of Nicorandil.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Amineptine.
OctamoxinOctamoxin may increase the serotonergic activities of Amineptine.
OlodaterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Olodaterol.
OmapatrilatThe serum concentration of Amineptine can be increased when it is combined with Omapatrilat.
OrciprenalineThe risk or severity of adverse effects can be increased when Amineptine is combined with Orciprenaline.
OtamixabanThe serum concentration of Amineptine can be increased when it is combined with Otamixaban.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Amineptine.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Amineptine.
PargylinePargyline may increase the serotonergic activities of Amineptine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amineptine.
PentobarbitalThe metabolism of Amineptine can be increased when combined with Pentobarbital.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Amineptine.
PerindoprilThe serum concentration of Amineptine can be increased when it is combined with Perindopril.
PhenelzinePhenelzine may increase the serotonergic activities of Amineptine.
PhenindioneAmineptine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Amineptine.
PhenobarbitalThe metabolism of Amineptine can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Amineptine.
PhenprocoumonAmineptine may increase the anticoagulant activities of Phenprocoumon.
PhentermineAmineptine may increase the stimulatory activities of Phentermine.
PhenylephrineAmineptine may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Amineptine.
PhosphoramidonThe serum concentration of Amineptine can be increased when it is combined with Phosphoramidon.
PirbuterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Pirbuterol.
PirlindolePirlindole may increase the serotonergic activities of Amineptine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Amineptine.
PrimidoneThe metabolism of Amineptine can be increased when combined with Primidone.
PrinomastatThe serum concentration of Amineptine can be increased when it is combined with Prinomastat.
ProcaterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Procaterol.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Amineptine.
QuinaprilThe serum concentration of Amineptine can be increased when it is combined with Quinapril.
QuinidineAmineptine may increase the QTc-prolonging activities of Quinidine.
RamiprilThe serum concentration of Amineptine can be increased when it is combined with Ramipril.
RasagilineRasagiline may increase the serotonergic activities of Amineptine.
RemikirenThe serum concentration of Amineptine can be increased when it is combined with Remikiren.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Amineptine.
RitodrineThe risk or severity of adverse effects can be increased when Amineptine is combined with Ritodrine.
RitonavirThe serum concentration of Amineptine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Amineptine can be increased when it is combined with Rivaroxaban.
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Amineptine.
SafrazineSafrazine may increase the serotonergic activities of Amineptine.
SalbutamolThe risk or severity of adverse effects can be increased when Amineptine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Salmeterol.
SaquinavirThe serum concentration of Amineptine can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Amineptine can be increased when it is combined with Saxagliptin.
SecobarbitalThe metabolism of Amineptine can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the serotonergic activities of Amineptine.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amineptine.
SimeprevirThe serum concentration of Amineptine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Amineptine can be increased when it is combined with Sitagliptin.
SpiraprilThe serum concentration of Amineptine can be increased when it is combined with Spirapril.
St. John's WortThe metabolism of Amineptine can be increased when combined with St. John's Wort.
TelaprevirThe serum concentration of Amineptine can be increased when it is combined with Telaprevir.
TemocaprilThe serum concentration of Amineptine can be increased when it is combined with Temocapril.
TerbinafineThe metabolism of Amineptine can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Amineptine is combined with Terbutaline.
ThiamylalThe metabolism of Amineptine can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Amineptine can be increased when combined with Thiopental.
ThiorphanThe serum concentration of Amineptine can be increased when it is combined with Thiorphan.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Amineptine.
TipranavirThe serum concentration of Amineptine can be increased when it is combined with Tipranavir.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Amineptine.
ToloxatoneToloxatone may increase the serotonergic activities of Amineptine.
TramadolAmineptine may increase the neuroexcitatory activities of Tramadol.
TrandolaprilThe serum concentration of Amineptine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amineptine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Amineptine.
UbenimexThe serum concentration of Amineptine can be increased when it is combined with Ubenimex.
VilanterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Vilanterol.
VildagliptinThe serum concentration of Amineptine can be increased when it is combined with Vildagliptin.
WarfarinAmineptine may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Amineptine can be increased when it is combined with Ximelagatran.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Amineptine.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Amineptine.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid St.John's Wort.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on September 12, 2007 03:05 / Updated on August 17, 2016 12:24